Articles tagged "Donors, marginal"

2020 American Transplant Congress
Widespread Deregulation of Metabolic Genes in Steatotic Livers Pre- And Post-Transplantation
A. R. Wolen¹, C. Kuscu², C. Kuscu², A. Bajwa², J. Eason², S. Sataphaty³, J. D. Eason¹, D. Maluf¹, V. Mas¹
¹Department of Surgery_ University of Tennessee, James D Eason Transplant Institute, Memphis, TN, ²Department of Surgery, Transplant Research Institute, James D. Eason Transplant Institute, University of Tennessee Health Science Center, Memphis, TN, ³Sandra Atlas Bass Center for Liver Diseases & Transplantation, Northshore University Hospital/Northwell Health, NYC, NY
*Purpose: The escalating obesity crisis is a double-edged sword for the field of liver transplantation; higher rates of fatty liver disease increase both the demand…
2020 American Transplant Congress
Sequential Protocol Biopsies Post-Liver Transplant from Donors with Moderate Macrosteatosis: What Happens to the Fat?
K. Croome, D. Livingston, C. Taner, R. Nakhleh
Mayo Clinic Jacksonville, Jacksonville, FL
*Purpose: The number of steatotic deceased donor livers encountered has continued to rise as a result of the obesity epidemic. Little is known about the…
2020 American Transplant Congress
Taking Liver Transplant to “The Friendly Skies”: A Novel Pilot Program Using Commercial Flights and Ride-Sharing Apps to Minimize Dry-Run Expenses and Expand Potential Donors
G. J. McKenna, N. Onaca, H. Fernandez, E. Martinez, A. Gupta, A. Wall, J. Bayer, R. Ruiz, G. Testa
Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX
*Purpose: Growth in liver transplantation means using marginal/DCD donors, however these often fail to yield a suitable organ. Organ procurement can require travelling significant distances,…
2020 American Transplant Congress
Multi- National Survey among Nephrologists & Transplant Surgeons about the Suitability & Acceptance of the Marginal Living- Kidney Donors with Obesity or Abnormal Blood Sugar Profile
Z. Arabi¹, M. A. Bukhari²
¹KAMC, Riyadh, Saudi Arabia, ²Taif University, Taif, Saudi Arabia
*Purpose: There are no clear guidelines about the suitability and acceptance of living- kidney donors with obesity or abnormal blood sugar profile.*Methods: To form a…
2020 American Transplant Congress
Post-Transplant Blood Borne Infectious Disease Testing in Recipients of Increased Risk Donor Livers: A Single Center Experience
J. Hendele
University of Washington, Seatttle, WA
*Purpose: Increasing the recovery and utilization of donor livers has become a key goal for transplant programs in the United States over the past decade.…
2020 American Transplant Congress
The Study of Continuous Renal Replacement Therapy Performing in Pre-Retrieval Management of Marginal Criteria Donor Lung: A Retrospective Control Study
J. Huang¹, X. Zheng², Z. Wang¹, M. Huang², J. Chen¹
¹Wuxi Lung Transplant Center, Wuxi People's Hospital affiliated to Nanjing Medical University, Wuxi, China, ²General ICU, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
*Purpose: Ex vivo lung perfusion (EVLP) has successfully been applied to the management of marginal donor lungs, while the high cost and equipment lacking restrict…
2020 American Transplant Congress
Development of a Novel Multidrug Combination to Defat Steatotic Rat Liver via Normothermic Machine Perfusion
M. Xu¹, F. Zhou¹, O. Ahmed¹, G. Upadhya¹, J. Jia¹, C. Lee¹, J. Xing¹, L. Ye¹, S. Shim¹, Z. Zhang¹, K. Byrnes², B. Wong¹, J. Kim¹, Y. Lin¹, W. Chapman¹
¹Surgery, Washington University, St. Louis, MO, ²Pathology and Immunology, Washington University, St. Louis, MO
*Purpose: Hepatic steatosis is now the leading cause of liver discards in deceased donors. Previous studies (Yarmush et al., Y defatting) have successfully reduced the…
2020 American Transplant Congress
Impact of Donor Multidrug-Resistant Organisms on Risk of Recipient Infection
J. A. Anesi¹, E. A. Blumberg¹, J. H. Han², D. H. Lee³, H. Clauss⁴, R. Hasz⁵, E. Molnar⁴, D. Alimenti¹, A. R. Motzer⁴, S. West⁵, W. B. Bilker¹, P. Tolomeo¹, E. Lautenbach¹, T. Prevention Epicenters Program⁶
¹University of Pennsylvania, Philadelphia, PA, ²GlaxoSmithKline, Rockville, MD, ³Drexel University, Philadelphia, PA, ⁴Temple University, Philadelphia, PA, ⁵Gift of Life Donor Program, Philadelphia, PA, ⁶Centers for Disease Control and Prevention, Atlanta, GA
*Purpose: Although there is concern about the use of donor organs that are infected or colonized with multidrug-resistant organisms (MDROs), their impact on solid organ…
2020 American Transplant Congress
Absence of Adverse Infectious Disease Outcomes in the Long-Term Follow-Up of Recipients of PHS Increased Risk Donor Organs: An Essential Tracking Program
L. Irwin, J. Fishman
Transplant Surgery, Massachusetts General Hospital, Boston, MA
*Purpose: 37-41% of deceased donors in Region I are considered “PHS increased risk for infectious disease transmission” (IR) individuals, our Center developed guidelines for the…
2020 American Transplant Congress
Temporal Trends in Utilization and Outcomes of DCD Livers for Liver Transplantation in the United States
K. R. Jackson, J. Motter, A. Massie, B. Philosophe, J. Garonzik-Wang, D. Segev
Johns Hopkins University, Baltimore, MD
*Purpose: Donation after cardiac death (DCD) livers represent a possible expansion to the donor pool, but are frequently discarded due to an increased mortality and…